Does phenylpiracetam hydrazide actually work?

There is no reliable human evidence. The compound has essentially no dedicated peer-reviewed pharmacology; documented data are limited to an anticonvulsant effect in rodents, and users often report subtle or minimal effects. Treat any nootropic claim as unproven.

Is it the same thing as phenylpiracetam?

No. It is the hydrazide analog: the amide group of phenylpiracetam is swapped for a hydrazide group. That is a distinct molecule (C12H15N3O2) with its own, largely unstudied profile, rather than the parent's documented stimulant and dopaminergic pharmacology.

Is it banned in competitive sport?

The parent phenylpiracetam (carphedon) is explicitly WADA-prohibited in competition. This hydrazide is not named on the list, but as a close structural analog it could be caught by WADA's similar-structure or similar-effect clause, so athletes should avoid it.

EmergingResearch compoundReference only

Phenylpiracetam Hydrazide

Name: Phenylpiracetam Hydrazide
Creator: MolekulaX

Hydrazide analog of phenylpiracetam (fonturacetam). A research chemical with essentially no dedicated human data; reference-only.

NootropicRacetamResearch chemicalRacetamPhenylpiracetamHydrazideDopamineGlutamateAcetylcholine

Pharmacology

ClassRacetam · Phenylpiracetam · Hydrazide

Primary targetRacetam pyrrolidinone core; presumed cholinergic and glutamatergic modulation (parent-inferred DAT inhibition)

Targets3 receptor targets

Half-lifeN/A (no PK data)

OnsetN/A (no established protocol)

EvidenceReference only

Affected systemsDopamineGlutamateAcetylcholine

Contents

WHAT IS PHENYLPIRACETAM HYDRAZIDE?

Detailed overview

Phenylpiracetam hydrazide (fonturacetam hydrazide) is a racetam in which the amide group of phenylpiracetam is replaced by a hydrazide group on the 2-oxo-4-phenylpyrrolidinone scaffold. It was first reported in 1980 by a Russian research group screening pyrrolidinone anticonvulsants, and in rodent electroshock models it showed anticonvulsant activity with an ED50 near 310 mg/kg. The hydrazide itself has essentially no dedicated peer-reviewed pharmacology; any nootropic or dopaminergic effect is inferred from the parent compound rather than measured. It is not an approved medicine anywhere and is sold only as a research chemical, so every mechanism, dose and effect statement below is speculative and reference-only.

Mechanism

Hydrazide analog of phenylpiracetam (parent-inferred)

Half-life

N/A (no PK data)

Legal status

Research chemical, not approved

Evidence

Reference-only (no human trials)

Receptor profile

Racetam pyrrolidinone core (presumed cholinergic/glutamatergic)Weak
Dopamine transporter (DAT), inferred from parentWeak
Seizure threshold / anticonvulsant activity (animal model)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

Overstimulation, irritability and insomnia, as a presumed class effect (not measured)
Headache, commonly associated with racetams, may relate to choline depletion
Unknown safety profile: no dedicated human toxicology or adverse-effect data exist
Unpredictable purity: as a research chemical, contamination and mislabeling are real risks
Anecdotal reports describe effects as often subtle or minimal, which may tempt higher, riskier dosing

Contraindications · 5

Pregnancy and breastfeeding: no safety data, should be avoided
Human consumption in general: not an approved medicine, intended for research use only
Hepatic or renal impairment: unknown metabolism and clearance, caution
Competitive athletes: the parent is WADA-prohibited and the analog may fall under the similar-structure clause
Epilepsy / seizure threshold: although anticonvulsant in animals, uncharacterized in humans, medical supervision advised

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

Drug Test Anal. 2023.

Unauthorized ingredients in 'nootropic' dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents.

Jędrejko K, et al.

PMID: 37357012Open

Zh Nevrol Psikhiatr Im S S Korsakova. 2024.

[Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use].

Gromova OA, et al.

PMID: 39269293Open

Basic Clin Pharmacol Toxicol. 2011.

Investigation into stereoselective pharmacological activity of phenotropil.

Zvejniece L, et al.

PMID: 21689376Open

Pharmacol Biochem Behav. 2017.

S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity.

Zvejniece L, et al.

PMID: 28743458Open

FAQ

Hydrazide analog of phenylpiracetam (fonturacetam). A research chemical with essentially no dedicated human data; reference-only.

Have a question about Phenylpiracetam Hydrazide?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

FormulaC12H15N3O2

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.